Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Therefore, use of rhEPO for treatment of tissue injury is limited by the potential side effects of increased erythrocyte mass and endothelial cell activation, which, in combination with activated platelet production, predisposes to thrombosis (6,7)
AOD-9604 Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Protocols | Limitations | Lead Researcher | References AOD-9604 Peptide Molecular Structure & Chemical Properties AOD-9604 represents a pioneering approach to peptide-based metabolic research, originally developed in the 1990s at Monash University in Australia as a potential anti-obesity therapeutic
The compounds safety and pharmacological profile have been comprehensively assessed in rodent models.In preclinical trials, including those involving ovariectomized (OVX) rat models, both low- and high-dose AOD-9604 regimens showed no significant toxicity
Beta-2 agonists
US$ 26.06
US$ 24.96
US$ 23.98
US$ 25.17
